Alembic obtains FDA OK for generic Desonide
Desonide is a low-potency corticosteroid indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Alembic’s Aleor Dermaceuticals has received the Food and Drug Administration’s approval for desonide cream, 0.05%, a generic of Padagis’ desonide.
The product is a low-potency corticosteroid indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Desonide cream had a market value of $12 million for the 12 months ending September 2022 according to IQVIA.